StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$93.81−5.56 (-5.60%)

Close on Nov 17, 2026Market cap $8.27BP/E –Yield –

Spyre Therapeutics, Inc. reported revenue of $0 for fiscal 2025. At the latest close the market valued the company at $8.27B.

Revenue
$0
FY2025
Operating income
-$201.34M
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026

Valuation

Market cap
$8.27B
P/E ratio
–
Price to sales
–
Price to book
7.51
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$0
Net income
-$178.92M

Trading

Next earnings
Feb 18, 2027 (estimated, after the close)
Previous close
$99.37
Open
$98.70
Day's range
$92.92 – $100.03
Volume
1,109,263
Average volume (20 days)
945,067
Index membership
Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
52-week range
$22.13 – $110.64
RSI (14 days)
52.8
Volatility (1 year)
66.7%
Relative volume
0.70×

On 1 of our idea list: Institutions accumulating

Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2016, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodSYRES&P 500DifferenceSYRE per yearS&P 500 per year
1 month+17.4%-4.0%+21.4 pts
3 months-10.3%-5.0%−5.3 pts
Year to date+186.4%+8.2%+178.1 pts
1 year+285.1%+11.2%+273.9 pts
3 years+815.2%+68.5%+746.7 pts+109.2%+19.0%
5 years-44.7%+67.3%−111.9 pts-11.2%+10.8%
10 years-39.5%+291.6%−331.1 pts-4.9%+14.6%

Thirteen years at a glance

Fiscal years 2013 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$201.34M

Net income

-$178.92M

EPS, diluted

–

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Spyre Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Spyre Therapeutics

Pharmaceutical Preparations

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company that creates long-acting monoclonal antibodies and combination therapies to treat inflammatory bowel disease and rheumatic conditions. Its drug development pipeline targets biological pathways including α4β7, TL1A, and IL-23, which are being advanced as individual therapies as well as fixed-dose pairwise combinations. The company focuses on conditions such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Because its product candidates remain in clinical evaluation, Spyre does not currently sell commercial products, though its prospective end-users are individuals suffering from these chronic immune-mediated disorders.

Company profile, executives and history

Spyre Therapeutics stock: common questions

What is Spyre Therapeutics's stock price?

SYRE closed at $93.81 on Nov 17, 2026, down 5.60% on the day. Over the past 52 weeks it traded between $22.13 and $110.64.

What is Spyre Therapeutics's market cap?

Spyre Therapeutics was worth $8.27B at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

How much revenue does Spyre Therapeutics make?

Spyre Therapeutics reported revenue of $0 for fiscal 2025.

Does Spyre Therapeutics pay a dividend?

No. Spyre Therapeutics has not paid a cash dividend over the last twelve months.

When does Spyre Therapeutics report earnings next?

Spyre Therapeutics is expected to report Q4 FY2026 results on Feb 18, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has SYRE stock performed over the past year?

Including dividends, SYRE returned +285.1% over the past year, against +11.2% for the S&P 500.

How many SYRE shares are sold short?

12M shares were sold short at the latest FINRA report, 16.54% of the float, or 12.7 days of average trading volume.

Who are Spyre Therapeutics's competitors?

Companies most similar to Spyre Therapeutics by business, industry and size include STTK, ACRS, DNTH, CRVS, MLTX.

See a number that looks wrong?